Cargando…
Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
Filoviruses cause sporadic but highly lethal outbreaks of hemorrhagic fever in Africa in the human population. Currently, no drug or vaccine is available for treatment or prevention. A previous study with a vaccine candidate based on the low seroprevalent adenoviruses 26 and 35 (Ad26 and Ad35) was s...
Autores principales: | Zahn, Roland, Gillisen, Gert, Roos, Anna, Koning, Marina, van der Helm, Esmeralda, Spek, Dirk, Weijtens, Mo, Grazia Pau, Maria, Radošević, Katarina, Weverling, Gerrit Jan, Custers, Jerome, Vellinga, Jort, Schuitemaker, Hanneke, Goudsmit, Jaap, Rodríguez, Ariane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516506/ https://www.ncbi.nlm.nih.gov/pubmed/23236343 http://dx.doi.org/10.1371/journal.pone.0044115 |
Ejemplares similares
-
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
por: Callendret, Benoit, et al.
Publicado: (2018) -
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
por: Callendret, Benoit, et al.
Publicado: (2018) -
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform
por: Salisch, Nadine C., et al.
Publicado: (2017) -
First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012) -
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
por: Bos, Rinke, et al.
Publicado: (2020)